In the News
Neo.Life features Iya Khalil in 2018 Biotech Breakthroughs and Big Ideas
In this January article, Neo.Life profiles the biggest biotech breakthroughs and big ideas for 2018, including thoughts from Iya Khalil, GNS co-founder and chief commercial officer. Iya speaks to the proliferation of emerging -omic data and how advances in artificial...
read morePPD Names Colin Hill, CEO of GNS Healthcare, to its Board of Directors
Pharmaceutical Product Development, LLC (PPD) today announced that Colin Hill has been named to the company’s board of directors. Hill is the chairman, chief executive officer and co-founder of GNS Healthcare, a leading precision medicine company. “Colin Hill is a...
read moreGenentech oncology collaboration with GNS featured in TechEmergence
October 11, 2017 by Jon Walker Genentech, a member of the Roche Group, this summer announced their own collaboration with Cambridge, MA-based GNS Healthcare. GNS Healthcare’s mission statement is to use the latest innovations in machine learning to turn biomedical...
read moreGenomeWeb Features GNS Healthcare’s Novel Parkinson’s Gene Discovery
Recently published research powered by GNS Healthcare, maker of a causal machine-learning platform for precision medicine, promises to unravel some of the mysteries of Parkinson's disease, specifically the rate of progression of the neurodegenerative condition. Being...
read moreGNS Co-Founders Included on 50+ Most Influential People of Color in Life Sciences & Healthcare
GNS co-founders Colin Hill and Dr. Iya Khalil have been included on the list of the 50+ Most Influential People of Color in Life Science and Healthcare. The list, compiled by networking organization Get Konnected, was officially unveiled at an event on September 19th...
read moreGNS Healthcare Adds $6M, Led by Amgen, for Machine Learning Tech
August 23, 2017 — Xconomy Boston — The investment arm of biotech giant Amgen has led a new $6 million round of funding in GNS Healthcare, CEO Colin Hill tells Xconomy. Amgen Ventures’ new investment is a part of the company’s Series C financing round, which now totals...
read moreBioCentury highlights GNS-Alexion partnership
Alexion rebuilding pipeline with big data deals August 10, 2017 – Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is rebuilding its early stage pipeline with two new deals focused on driving rare disease discovery with big genomic data. The company partnered with Sema4...
read moreFierceBiotech features Alexion-GNS Partnership Targeting Rare Diseases
Alexion inks genomics pacts to continue R&D reboot August 11, 2017 – Alexion has teamed up with GNS Healthcare and Sema4 to advance its rare disease R&D agenda. The partnerships give Alexion access to modeling and simulation software used by Celgene and a partner to...
read moreRare Disease Report Covers Alexion-GNS REFS Licensing Agreement
Rare Disease Treatments to Be Discovered by Machine Learning and Simulation Platform
read moreGNS Co-Founder Iya Khalil Interviewed in The Pink Sheet
At the 2017 BIO International Convention, GNS Co-Founder and Chief Commercial Officer Iya Khalil sat down with Laura Helbling, the Director of Research at Prevision Policy and a Senior Writer at Pink Sheet to discuss machine learning in drug development. The...
read more